Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders

PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at...
April 29, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMD

DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potentialBiophytis plans to initiate Phase 1 clinical trial in the second half of 2021 PARIS...
April 27, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis - Convening of Another Combined General Meeting at a Later Date

PARIS and CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at...
April 26, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

PARIS and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are...
April 13, 2021 17:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS Identifies False Report Regarding COVA study

PARIS and CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of...
March 22, 2021 03:00 ET | Source: BIOPHYTIS SA

BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19

The Company receives a favorable opinion from the DMC on the safety of Sarconeos (BIO101) in the COVA study following first interim analysisPatient enrollment has now reached 97 of the 155 planned for...
March 19, 2021 18:00 ET | Source: BIOPHYTIS SA

Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis Against Negma Group Ltd

PARIS and CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
March 10, 2021 22:08 ET | Source: BIOPHYTIS SA

Biophytis’ Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors

Legally required documents for shareholders’ votes are available on Biophytis website PARIS and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth...
February 26, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Reports 2020 Full Year Results

PARIS and CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
February 17, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium

Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory AuthoritiesThese approvals follow the previous authorizations...